Quantitative Brand Name Testing for a Global Medical Device Company
15th of September is observed as the World Lymphoma Awareness Day (WLAD) to raise awareness, while September is the Lymphoma Awareness Month. In connection to the WLAD, we present an infographic depicting the burden of the two main sub-types of Lymphoma - Hodgkin's and Non-Hodgkin's disease - in the APAC region.
The advent of rituximab itself changed the prognosis of Non-Hodgkin’s lymphoma. Being a very specific, chimeric monoclonal antibody, it targets only the cells expressing CD20 marker.
. . . will help in understanding the overall trends in terms of disease burden and help in allocating funds accordingly
... newer drugs like osimertinib, alectinib, crizotinib etc. are also available ... Some of these molecular therapies have exorbitant prices and are beyond the reach of average citizens.